Electron beam tomography as an endpoint for clinical trials of antiatherosclerotic therapy
1EBT Research Foundation, 224 Lauderdale Road, Nashville, TN 37205, USA. praggi@attglobal. net
Insights
Electron beam tomography offers a noninvasive method to monitor coronary artery disease regression. This approach aids in assessing antiatherosclerotic therapies, providing a low-risk, cost-effective alternative to traditional methods.
Area of Science:
- Cardiovascular Medicine
- Medical Imaging
- Preventive Cardiology
Background:
- Current antiatherosclerotic therapies effectively reduce cardiovascular events, making further improvements challenging to demonstrate.
- Coronary artery disease regression, evidenced by angiographic studies, serves as a valid surrogate endpoint for therapeutic efficacy.
- Coronary angiography, while effective, is invasive and costly, necessitating alternative methods for monitoring treatment effectiveness.
Purpose of the Study:
- To explore the utility of electron beam tomography (EBT) as a noninvasive surrogate endpoint for assessing antiatherosclerotic therapies.
- To evaluate the potential of EBT in quantifying vascular calcification for monitoring coronary artery disease (CAD) progression and regression.
- To establish EBT as a low-cost, low-risk alternative for serial monitoring of CAD treatment effectiveness.
Main Methods:
- Utilizing electron beam tomography (EBT) to noninvasively visualize the coronary artery tree.
- Quantifying vascular calcification, a key marker of atherosclerotic disease, using EBT.
- Comparing EBT findings with established surrogate endpoints and clinical outcomes in preliminary studies.
Main Results:
- EBT enables noninvasive detection and quantification of vascular calcification in the coronary arteries.
- Preliminary data suggest a correlation between EBT-assessed calcification and atherosclerotic disease burden.
- EBT offers a potential for serial monitoring of antiatherosclerotic therapy effectiveness at reduced patient risk and cost.
Conclusions:
- Electron beam tomography is a promising noninvasive tool for assessing coronary artery disease regression.
- Vascular calcification measured by EBT can serve as a valuable surrogate endpoint for antiatherosclerotic therapy evaluation.
- EBT provides a feasible, low-risk, and cost-effective method for the serial monitoring of cardiovascular disease treatment.
Abstract:
Current antiatherosclerotic therapies are highly effective and have induced a factual reduction in morbidity and mortality related to atherosclerotic disease. This makes it difficult for clinical researchers to demonstrate a further reduction in hard events. On the other hand, angiographic studies have conclusively demonstrated that coronary artery disease regression can be used as a valid surrogate endpoint. In fact, small improvements in luminal diameter stenosis corresponded to a substantial reduction in event rates. However, because coronary angiography is invasive and expensive, other surrogate endpoints may be more desirable to ascertain the effectiveness of therapy. With electron beam tomography imaging the coronary artery tree is visualized noninvasively and vascular calcification, a marker of atherosclerotic disease, is easily detected and its extent quantified. Preliminary studies have shown that this technology provides an opportunity to serially monitor the effectiveness of medical therapy for coronary artery disease at low cost and low risk for the patient.
Related Concept Videos
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET